Top-Rated Stocks Blowing the Doors Off This Market

Recs

1

Be A Motley Fool Millionaire!

David Gardner's top pick took an epic run of 1,334%! See what he’s recommending that you buy NEXT.

No one has perfect foresight, but let's be honest: The market is full of people who, as Oscar Wilde would say, know "the price of everything and the value of nothing." Far too often -- over the past year especially -- investors have been pitched sensational stock recommendations, only to be left high and dry as shares crumble.

To hunt down top-recommended stocks that have been rewarding investors accordingly, I summoned our Motley Fool CAPS community to point out a few four- or five-star stocks that have been shootin' for the moon in recent months.

While not formal buy recommendations, these three-month bloomers caught my attention:

Company

13-Week Price Change

Recent Share Price

Forward P/E Ratio

CAPS Rating  
(out of 5)

Allied Irish Banks (NYSE: AIB)

102%

$8.05

N/A

*****

CVS Caremark (NYSE: CVS)

24%

$36.77

12.31

****

Garmin (Nasdaq: GRMN)

55%

$32.32

14.24

****

Intuitive Surgical (Nasdaq: ISRG)

51%

$224.90

33.54

****

Boston Beer (NYSE: SAM)

41%

$39.87

20.12

****

Data from Motley Fool CAPS and Yahoo! Finance as of Aug. 31.

You can rerun the CAPS screen I used by clicking here.

A closer look at Garmin
GPS manufacturer Garmin went from a company many assumed could do no wrong to one plagued by an army of naysayers maniacally foretelling how Apple (Nasdaq: AAPL) and Research In Motion (Nasdaq: RIMM) will send it down in flames.

That may be true ... to a point. Small, portable, smartphones with ever-improving navigation functions indeed erode Garmin's once-dominant position. As CAPS member McCracker1 writes:

GPS is now commoditized. iPhones and [BlackBerry] handsets have GPS that is clean looking and easy to use. Why are people going to spend $ on Garmin's stuff? They are not, that's why. 10 million iphones a year in the US means a definite 10 million people not needing Garmin. Add the [BlackBerry] sales and the PALM Pre...forget about Garmin.

But let's look at the other side of the argument: Smartphone navigation systems are beneficial for low-key, no-need-to-be-terribly accurate, directions. Anyone with an iPhone knows that the map function, while pretty handy, isn't extraordinarily precise. It's good, just not Garmin good.

This is only important to bring up because:

  • You can't navigate a plane or a boat with a smartphone.
  • You can't trust a smartphone on a hike in the wilderness. Or a hunting expedition. Or a fishing outing. Or on a bicycle. Or a golf course.

Point being: Sure, Garmin isn't nearly as powerful as it was a few years ago. But rumors of its death are greatly exaggerated. Rapid, fanatical, growth might be dead; neither the company, nor any of its business units, are going anywhere.

From an investment standpoint, this becomes important when you consider shares trade for only about 14 times forward earnings, the company has zero debt, it has nearly $5 per share in cash, and it's roughly 43% owned by insiders. Not only is Garmin not about to explode, it's wonderfully run, and fairly cheap, too. As CAPS member fastfreddy7 wrote earlier this year:

Garmin has a huge balance sheet. Even if you discount property and intangibles to 0, they still have about $1.5Bill on the [balance] sheet, which is over 1/3 of their market cap. This is for a company that is still earning $150Mill a quarter, and are continuing to innovate. Their enterprise value to forward earnings ratio is in the 4-5 ratio. and they have about 40% employee ownership. everytime I look for another stock, I keep coming back to Garmin. The knock is that they will get displaced by the handset providers, but I believe that is overstated, they continue to find great markets that handsets don't fit, like running, aviation, boating, etc.

Your turn to chime in
Have your own take on Garmin? More than 140,000 investors use CAPS to share ideas and swap opinions. Check it out and speak your mind. It's 100% free to participate.

For related Foolishness:                                               

“Make Big Money With Options” Motley Fool CFO Ollen Douglass recently made over $100,000 buying options on 7 well known stocks. Now we’re committed to turning his small fortune into a massive one! And we want you to join us! Enter your email address to hear more:

Fool contributor Morgan Housel doesn't own shares in any of the companies mentioned in this article. Intuitive Surgical is a Motley Fool Rule Breakers pick. Apple is a Stock Advisor recommendation. Allied Irish Banks and Garmin are Global Gains picks. The Fool owns shares of Allied Irish Banks, and has a disclosure policy.

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On August 31, 2009, at 1:39 PM, MotleyGulibles wrote:

    Motley Fool recommended AIB at $40.00 and it came crashing down to 1. Should I continue?

    My advice, toss the Foolish Fool paid services and embrace its far more astute community.

  • Report this Comment On September 06, 2009, at 10:56 AM, Teacherman1 wrote:

    An interesting article Morgan, and one which is worth more than the dismissive post made by MotleyGuibles.

    Not trying to pick a fight, or put anyone down, but know whose advice you are following. MotleyGuibles has a higher ranking, score and rating than I do, but it is interesting to note that it is base primarily on one pick, without which, all of the above would plunge from the stratosphere and back to earth.

    Enough on the negative. We all make recommendations based on what we know, believe, and perceive at the time they are made. It is still up to the individual to do their own research and make their investments based on that.

    I am long on AIB (at a very good price) and believe it will pay off very well, but not tomorrow. My personal investment horizon is in the 2-3 year range. My reasons for picking this stock (and putting real money in it) have been previously posted, but I will briefly repeat the main points.

    AIB is a major player in a country whose government is very interested in fostering a growing economy. AIB did not get into the shape they are now in because of blindly making foolhardy loans, but because the world economy came to a screeching halt, and that of Ireland along with it.

    The Irish Govt. is in the process of using a vehicle known as NAMA, to buy out and hold long term the (temporarily) bad loans on their books with the intention of freeing up the banks to extend more credit, and then sell them later to get their money back.

    AIB was doing what the Govt wanted done, which was make development loans to facilitate and expand the growth of business in Ireland.

    Will this work? That is your call to make.

    The Royal Bank of Canada seems to think so, since they have expressed an interest in taking a position in AIB when the NAMA situation gets further along.

    I believe it will, but like anyone else, I could be wrong.

    I am in at around $5.00, and feel very comfortable with watching and waiting to see what happens.

    JMO and worth exactly what I am charging for it.

Add your comment.

Compare Brokers

TD AMERITRADE
more info
ShareBuilder
more info
Power E*Trade

more info
Scottrade
more info
Fool Disclosure

DocumentId: 974740, ~/Articles/ArticleHandler.aspx, 12/1/2009 11:31:32 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

The Must-Read Story on Fool.com
The Public Health-Care Plan's Problem

Related Tickers

12/1/2009 10:47 AM
SAM $43.19 Up +1.10 +2.61%
The Boston Beer Co… CAPS Rating: ****
RIMM $59.08 Up +1.19 +2.06%
Research In Motion… CAPS Rating: ***
AIB $4.64 Down -0.12 -2.52%
Allied Irish Banks… CAPS Rating: ****
GRMN $29.82 Down -0.06 -0.20%
Garmin Ltd. CAPS Rating: ***
ISRG $283.75 Up +3.21 +1.14%
Intuitive Surgical… CAPS Rating: ****
AAPL $201.33 Up +1.42 +0.71%
Apple, Inc. CAPS Rating: ***
CVS $31.27 Up +0.26 +0.85%
CVS Caremark Corp CAPS Rating: ****

Community: Investing Wiki

Term Of The Hour

PDUFA: The Prescription Drug User Fee Act (PDUFA) is a law enacted by Congress that gives powers to the FDA.

Want to learn more or edit this definition?
Click here to read more!